The market may be sinking today, but the same cannot be said for the Mesoblast Ltd (ASX: MSB) share price.
In morning trade, the biotech companyâs shares rocketed as much as 23% to $1.14.
The Mesoblast share price has pulled back a touch since then but remains up 13% to $1.03.
Why is the Mesoblast share price rocketing higher?
Investors have been buying the companyâs shares after it was given some good news by the United States Food and Drug Administration (FDA).
According to the release, the FDAâs Office of Therapeutic Products has accepted the companyâs Biologics License Application resubmission for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).
And while this is not an approval, it is a big step in the right direction. Furthermore, the release notes that the FDA considers the resubmission to be a complete response to previous feedback and has set a Prescription Drug User Fee Act (PDUFA) goal date of 2 August.
What is a PDUFA?
My US colleagues cover the PDUFA in detail here. But hereâs a summary:
The PDUFA’s primary goal was to authorize the FDA to collect fees from drugmakers to help pay for the FDA staff needed to review regulatory filings for drugs. But the pharmaceutical industry objected to paying money to the FDA without anything guaranteed in return. The PDUFA helps the FDA by providing the agency with a way to generate money and establishes a set timeline for the agency to make approval decisions.
All in all, this guarantees that Mesoblast will have an answer from the FDA by 2 August for remestemcel-L in the treatment of children with SR-aGVHD.
Mesoblastâs Chief Executive, Silviu Itescu, was pleased with the news. He said:
Over the last two years we have worked tirelessly to address the issues previously raised by FDA. We look forward to working closely with the Agency over the review period with the aim to make remestemcel-L available as a therapy for children suffering from SR-aGVHD.
The post Mesoblast share price rockets 23% on FDA news appeared first on The Motley Fool Australia.
Should you invest $1,000 in Mesoblast Limited right now?
Before you consider Mesoblast Limited, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Mesoblast Limited wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks
*Returns as of March 1 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Why De Grey, Kogan, Mayne Pharma, and Mesoblast shares are charging higher
- 2 ASX All Ords shares smashing new 52-week highs on Thursday
- Mesoblast share price soars 11% on FDA update
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/18Fy7qU
Stock Pick 